Javadzadeh Alireza, Ghorbanihaghjo Amir, Adl Farzad Hami, Andalib Dima, Khojasteh-Jafari Hassan, Ghabili Kamyar
Nikookari Eye Hospital, Tabriz University of Medical Sciences, Tabriz, Iran.
Mol Vis. 2013;19:62-8. Epub 2013 Jan 10.
To determine the benefits of calcium dobesilate (CaD) administration on endothelial function and inflammatory status in patients with diabetic retinopathy through measurement of serum levels of endothelin-1 and high-sensitivity C-reactive protein (hsCRP).
In a double-blind, randomized clinical trial, 90 patients with either severe nonproliferative or proliferative diabetic retinopathy and with blood glucose level of 120-200 mg/dl were randomly allocated to treatment with either CaD tablets (500 mg daily) or placebo for 3 months. Visual acuity, intraocular pressure, and macular status were performed before the study. The serum levels of endothelin-1 and hsCRP were evaluated in both groups before and at the third month of the trial.
The median serum level of hsCRP significantly differed between the groups 3 months following the CaD or placebo administration (2.2 mg/l in the CaD group versus 3.7 mg/l in the placebo group, p=0.01). The mean endothelin-1 serum level was 0.69±0.32 pg/ml in the CaD group and 0.86±0.30 pg/ml in the placebo group (p=0.01). Furthermore, in the CaD group, the serum levels of both endothelin-1 and hsCRP were significantly decreased 3 months after administration of CaD (p<0.001).
Administration of the CaD in the patients with diabetic retinopathy may reduce the serum levels of endothelin-1 and hsCRP. This might imply amelioration of the endothelial function and inflammatory status following CaD therapy in these patients.
通过测量血清内皮素-1和高敏C反应蛋白（hsCRP）水平，确定服用羟苯磺酸钙（CaD）对糖尿病视网膜病变患者内皮功能和炎症状态的益处。
在一项双盲、随机临床试验中，90例患有严重非增殖性或增殖性糖尿病视网膜病变且血糖水平为120 - 200mg/dl的患者被随机分配接受CaD片（每日500mg）或安慰剂治疗3个月。在研究前进行视力、眼压和黄斑状态检查。在试验前及试验第三个月时评估两组患者血清内皮素-1和hsCRP水平。
服用CaD或安慰剂3个月后，两组患者hsCRP的血清中位数水平存在显著差异（CaD组为2.2mg/l，安慰剂组为3.7mg/l，p = 0.01）。CaD组内皮素-1血清平均水平为0.69±0.32pg/ml，安慰剂组为0.86±0.30pg/ml（p = 0.01）。此外，在CaD组中，服用CaD 3个月后内皮素-1和hsCRP的血清水平均显著降低（p<0.001）。
糖尿病视网膜病变患者服用CaD可能会降低血清内皮素-1和hsCRP水平。这可能意味着在这些患者中，CaD治疗后内皮功能和炎症状态得到改善。
